Animal Stem Cell Therapy Market Size
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 268.55 Million |
| Market Size (2030) | USD 348.83 Million |
| CAGR (2025 - 2030) | 5.37% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Animal Stem Cell Therapy Market Analysis
The Animal Stem Cell Therapy Market size is estimated at USD 268.55 million in 2025, and is expected to reach USD 348.83 million by 2030, at a CAGR of 5.37% during the forecast period (2025-2030).
Animal stem cell therapy is an advanced veterinary medical approach that leverages stem cells derived from animals to address injuries and various medical conditions in animals. The increasing prevalence of chronic diseases in animals, including inflammatory bowel disease, osteoarthritis, atopic allergies, and chronic kidney disease, will increase the demand of advanced treatment solutions such as animal stem cell therapy. For example, an article published by Companion Animal Health (a division of LiteCure, LLC) in April 2024 highlighted that osteoarthritis (OA) accounts for at least 80% of lameness and joint disease cases in companion animals. The rising incidence of OA globally is attributed to factors such as increasing obesity rates and longer life expectancy in animals. Furthermore, a retrospective study published in the International Journal of Veterinary Science and Animal Husbandry in October 2024 analyzed 2,456 dogs brought to the small animal medicine outpatient unit of the Veterinary Clinical Complex, Veterinary College and Research Institute, to evaluate the prevalence of chronic kidney disease (CKD). The study revealed that dogs aged 4 to 6 years exhibited the highest incidence of CKD compared to other age groups, with male dogs (70.77%) being more affected than female dogs (29.23%). The overall incidence rate of CKD in dogs was reported at 2.64% (65 dogs). These factors collectively underscore the growing demand for innovative treatment solutions like stem cell therapy, which is expected to drive the market's growth during the forecast period.
Additionally, the global rise in pet ownership and continuous advancements in stem cell research are driving the growth of the animal stem cell therapy market. For example, data from the 2024 Shelter Animal Count report indicates that, during the first half of 2024, approximately 3,118,000 dogs and cats entered shelters and rescue facilities across the United States. Of these, 1,553,000 were dogs, while 1,565,000 were cats. This global rise supports global animal stem cell therapy with increase in the demand of advanced treatment solutions.
Furthermore, according to 2024 statistics from the World Population Review, the United States leads globally in pet ownership, with an estimated 70 million domestic dogs and 74 million domestic cats. Brazil ranks second in terms of dog ownership, with approximately 35 million domestic dogs, which is nearly half the number found in the United States. Similarly, China holds the second position globally for cat ownership, with an estimated 53 million pet cats, although this figure remains significantly lower than that of the United States.
Moreover, advancements in stem cell research, particularly the growing adoption of mesenchymal stem cell therapy over traditional regenerative medicine, are driving the growth of the animal stem cell therapy market. For instance, according to an article published in the National Center for Biotechnology Information (NCBI) Journal in April 2024, mesenchymal stem cell therapies have recently gained prominence as a highly effective alternative in regenerative medicine. The increasing application of these cells in veterinary medicine has led to notable progress in addressing various medical conditions in animals. These trends in pet adoption, coupled with advancements in veterinary medicine, are expected to create substantial opportunities for the animal stem cell therapy market during the forecast period.
The animal stem cell therapy market is expected to witness significant growth, driven by advancements in stem cell research, a global increase in pet ownership, and the rising prevalence of chronic diseases in animals. These factors collectively indicate a promising future for the market, with opportunities for innovation and expansion.
However, the high cost of stem cell therapy treatment, lack of veterinary professionals, and low accessibility in low-income countries restrain the market growth.
Animal Stem Cell Therapy Market Trends
Allogeneic Segment is Expected to Witness Significant Growth Over the Forecast Period
Allogeneic stem cell therapy involves using stem cells derived from a donor animal, which are then processed and stored for therapeutic use in other animals. This approach has gained significant attention due to its scalability, convenience, and improved therapeutic results compared to autologous therapies, where stem cells are sourced directly from the treated animal. By avoiding invasive procedures, allogeneic therapies simplify the treatment process, as the stem cells are pre-collected and readily available for immediate use. This readiness ensures timely treatment, especially in urgent cases. For instance, a study published in the National Center for Biotechnology Information (NCBI) Journal in October 2023 highlighted the successful use of allogeneic stem cell therapy in treating tendon injuries in a racehorse, enabling the animal to recover and return to competitive performance within a few months. This underscores the effectiveness of allogeneic therapies in addressing critical veterinary challenges. Therefore, the advantages of allogeneic stem cell therapy, such as its ease of use, scalability, and superior therapeutic outcomes, make it a preferred choice over autologous stem cell therapy in many applications.
Furthermore, a study published by the American Veterinary Medical Association in February 2024 highlighted the potential of allogeneic stem cell therapy in treating spinal cord injuries in canines. The research, conducted on a canine model with experimentally induced spinal cord injuries, demonstrated that intrathecally delivered labeled stem cells were detected at the injury site through histopathological analysis at both one- and four-weeks post-injury. The findings revealed that allogeneic stem cell therapy significantly enhanced functional recovery, reduced cell death, and promoted cell proliferation. Additionally, the therapy stimulated key biological processes, including neurogenesis, oligodendrogenesis, synaptogenesis, and angiogenesis, which are critical for tissue repair and regeneration. These results underscore the growing potential of allogeneic stem cell therapy as a transformative solution in veterinary medicine, driving advancements in the treatment of complex conditions and supporting market growth.
Hence, the scalability, ease of application, and enhanced therapeutic potential of the allogenic segment are expected to significantly contribute to its growth in the animal stem cell therapy market. These factors position the allogenic segment as a key driver for advancements and adoption within this market.
North America is Anticipated to Hold a Significant Share in the Animal Stem Cell Therapy Market
North America is anticipated to hold a signficant share in the market, driven by factors such as rising expenditure on pet healthcare, increasing demand for advanced veterinary treatments, and growing rates of pet ownership. The region's well-established biotechnology industry, combined with significant investments in research and development, creates a strong platform for market expansion. For example, a recent survey conducted by the American Veterinary Medical Association in November 2024 highlighted a notable increase in pet healthcare spending. Approximately 86.8% of dog owners reported having a regular veterinarian or veterinary practice, while 77.1% of cat owners indicated the same in 2024. Among these respondents, the majority of dog owners (56.5%) visited their veterinarian twice, whereas the highest percentage of cat owners (44.9%) visited only once. The average annual expenditure on pets, excluding adoption or purchase costs, was recorded at USD 1,515 in 2023 and slightly increased to USD 1,516 in 2024. Henceforth, this rising expenditure on pet healthcare and increasing demand for advanced veterinary treatments are the factors influencing the regional dominance.
Furthermore, the growing number of campaigns and workshops aimed at promoting awareness of animal stem cell therapy among pet owners and organizations focused on exotic animals is significantly contributing to regional market growth. For example, in October 2023, VetStem organized a specialized workshop dedicated to wildlife conservation through stem cell technology. This event convened 45 global experts in stem cell science, providing a platform for sharing knowledge, exchanging best practices, and exploring innovative applications of stem cell technology to advance wildlife conservation initiatives. Such efforts are expected to enhance the adoption of stem cell therapies and drive market expansion in the coming years.
Moreover, key market players are actively working on expanding their operational footprint, which is expected to unlock significant growth opportunities and drive market expansion in the region. For example, in March 2023, VetStem, Inc. announced the expansion of its manufacturing and research and development facilities in San Diego. These upgraded facilities are intended to support VetStem's internal programs, facilitate manufacturing for its sister company, Personalized Stem Cells (PSC), and provide contract manufacturing services for new veterinary biologics. This strategic move underscores the company's commitment to innovation and its efforts to cater to the growing demand for advanced veterinary treatments.
Therefore, owing to the factors mentioned above, such as growing pet healthcare expenditures, growing number of campaigns, and expansion of the key players in the region drives the growth of the studied market in the North American region.
Animal Stem Cell Therapy Industry Overview
The animal stem cell therapy market is moderately fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold significant market share and are well known include VetStem, Inc., J-ARM Co., Ltd., Vetcell Therapeutics, Magellan Stem Cells, Aratana Therapeutics, Inc., Stemcell X, Boehringer Ingelheim International GmbH, MediVet Biologics, LLC, AniCell Biotech, Medregoamong others.
Animal Stem Cell Therapy Market Leaders
-
VetStem, Inc.
-
Aratana Therapeutics, Inc.
-
Stemcell X
-
Boehringer Ingelheim International GmbH
-
Medrego
- *Disclaimer: Major Players sorted in no particular order
Animal Stem Cell Therapy Market News
- June 2024: the Food and Drug Administration (FDA) granted approval for clinical trials at the Cornell University Hospital for Animals (CUHA) to investigate the use of stem cells in treating musculoskeletal and neurological disorders in dogs and horses. This positions CUHA as a prominent institution in veterinary regenerative medicine research. The primary objective is to enhance recovery from injuries in animals and alleviate their discomfort. These advancements signify a significant step forward in improving animal healthcare through innovative treatments.
- May 2024: VetStem, Inc. announced the successful completion of the Food and Drug Administration (FDA) review for its allogeneic off-the-shelf cell therapy product, PrecisePRP Equine, in the United States. This product is designed to deliver an equine-specific source of concentrated platelets in plasma, intended for intra-articular administration in horses. The development of PrecisePRP Equine represents a significant advancement in equine veterinary medicine, offering a targeted solution for joint-related conditions in horses.
Animal Stem Cell Therapy Industry Segmentation
As per the scope of the report, stem cells are unique biological cells capable of transforming into various specialized cell types, including blood, bone, muscle, and cartilage. In the context of animal stem cell therapy, these cells are harvested from the animal itself and strategically administered to repair or regenerate damaged tissues or organs. This innovative therapeutic approach is gaining traction in veterinary medicine due to its potential to address a wide range of medical conditions effectively.
The animal stem cell therapy market is segmented into type, application, animal type, end-user, and geography. By type, the market is segmented into allogeneic and autologous. By application, the market is segmented into wound healing, osteoarthritis, tendonitis, inflammatory bowel disease, leukemia, bone repair, and others. By animal type, the market is segmented into companion animals and livestock animals. By end-user, the market is segmented into veterinary hospital, veterinary clinics, research institutes. By geography, the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. For each segment, the market sizing and forecasts have been done on the basis of revenue (USD).
| By Type | Allogeneic | ||
| Autologous | |||
| By Application | Wound Healing | ||
| Osteoarthritis | |||
| Tendonitis | |||
| Imflammatory Bowel Disease | |||
| Leukemia | |||
| Bone Repair | |||
| Others | |||
| By Animal Type | Companion Animals | ||
| Live Stock Animals | |||
| By End User | Veterinary Hospital | ||
| Veterinary Clinics | |||
| Research Institutes | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Rest of the World | |||
Animal Stem Cell Therapy Market Research FAQs
How big is the Animal Stem Cell Therapy Market?
The Animal Stem Cell Therapy Market size is expected to reach USD 268.55 million in 2025 and grow at a CAGR of 5.37% to reach USD 348.83 million by 2030.
What is the current Animal Stem Cell Therapy Market size?
In 2025, the Animal Stem Cell Therapy Market size is expected to reach USD 268.55 million.
Who are the key players in Animal Stem Cell Therapy Market?
VetStem, Inc., Aratana Therapeutics, Inc., Stemcell X, Boehringer Ingelheim International GmbH and Medrego are the major companies operating in the Animal Stem Cell Therapy Market.
Which is the fastest growing region in Animal Stem Cell Therapy Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Animal Stem Cell Therapy Market?
In 2025, the North America accounts for the largest market share in Animal Stem Cell Therapy Market.
What years does this Animal Stem Cell Therapy Market cover, and what was the market size in 2024?
In 2024, the Animal Stem Cell Therapy Market size was estimated at USD 254.13 million. The report covers the Animal Stem Cell Therapy Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Animal Stem Cell Therapy Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Animal Stem Cell Therapy Industry Report
Statistics for the 2025 Animal Stem Cell Therapy market share, size and revenue growth rate, created by Mordor Intelligenceâ„¢ Industry Reports. Animal Stem Cell Therapy analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
